Beranda4547 • TYO
add
Kissei Pharmaceutical Co Ltd
Tutup sebelumnya
¥3.700,00
Rentang hari
¥3.705,00 - ¥3.800,00
Rentang tahun
¥3.000,00 - ¥4.270,00
Kapitalisasi pasar
180,39 M JPY
Volume Rata-Rata
73,72 rb
Rasio P/E
14,18
Hasil dividen
2,28%
Bursa utama
TYO
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (JPY) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 23,20 M | 11,12% |
Biaya operasional | 9,26 M | 14,14% |
Laba bersih | 3,59 M | 35,05% |
Margin laba bersih | 15,48 | 21,60% |
Penghasilan per saham | — | — |
EBITDA | 3,52 M | 10,84% |
Tarif pajak efektif | 18,37% | — |
Neraca
Total aset
Total liabilitas
| (JPY) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 44,46 M | 2,90% |
Total aset | 248,93 M | 8,96% |
Total liabilitas | 37,61 M | 21,87% |
Total ekuitas | 211,32 M | — |
Saham yang beredar | 42,81 jt | — |
Harga terhadap nilai buku | 0,75 | — |
Tingkat pengembalian aset | 2,41% | — |
Tingkat pengembalian modal | 2,83% | — |
Arus Kas
Perubahan kas bersih
| (JPY) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 3,59 M | 35,05% |
Kas dari operasi | — | — |
Kas dari investasi | — | — |
Kas dari pembiayaan | — | — |
Perubahan kas bersih | — | — |
Arus kas bebas | — | — |
Tentang
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
Didirikan
9 Agu 1946
Kantor pusat
Situs
Karyawan
1.779
